AZN
$191.29
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Intraday
Recent News
Big drugmakers must face US overcharge claims on medications for low-income patients
By Jonathan Stempel March 17 (Reuters) - A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds
AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
AbbVie slips below its 50-day SMA, signaling short-term weakness, but strong drug growth and a solid long-term uptrend may keep investors holding or buying dips
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU
AZN wins the EU nod for Imfinzi in early gastric and GEJ cancers, backed by strong survival data and expanding its blockbuster oncology footprint.
Imfinzi EU Approval Expands AstraZeneca Gastric Cancer Reach For Investors
AstraZeneca has received European Union approval for Imfinzi in combination with FLOT chemotherapy for early-stage and locally advanced gastric and gastroesophageal cancers. The decision is based on positive overall survival and event free survival data from the Phase III MATTERHORN trial. The approval significantly broadens AstraZeneca's oncology offering, a segment that accounts for over 40% of company revenue. For investors tracking AstraZeneca (LSE:AZN), this approval adds a new...
Why This Dimensional International ETF Belongs in Every Retiree’s Core Portfolio
Retirees building international exposure face a familiar dilemma: broad index funds offer diversification but treat every stock equally regardless of quality. Dimensional International Core Equity Market ETF (NYSEARCA:DFAI) tilts toward smaller companies, lower-priced stocks relative to their fundamentals, and higher-profitability businesses within the international universe. The goal is capturing long-run return premiums that academic research ... Why This Dimensional International ETF Belongs